Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP10 | Q14694 | 5/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1924541 | 0.93 | KDM4E (0.46) | USP10PTGDR2AKR1B1KDM4EALDH1A1 | |
| SCHEMBL1924088 | 0.89 | PTGDR2 (0.47) | USP10PTGDR2AKR1B1KDM4EALDH1A1 | |
| SCHEMBL1923303 | 0.88 | AKR1A1 (0.44) | PTGDR2AKR1B1KDM4EALDH1A1POLB | |
| SCHEMBL1923514 | 0.87 | EGFR (0.48) | USP10KDM4EALDH1A1POLBMAPT | |
| SCHEMBL1923682 | 0.86 | USP10 (0.49) | USP10ALDH1A1POLBMAPTGRM2 | |
| SCHEMBL1924231 | 0.86 | PTGDR2 (0.44) | USP10PTGDR2CYP2C9AKR1B1KDM4E | |
| SCHEMBL27775353 | 0.85 | USP10 (0.51) | USP10POLBMAPTGRM2 | |
| SCHEMBL1923644 | 0.85 | USP10 (0.43) | USP10PTGDR2GRM2NPSR1 | |
| SCHEMBL1923492 | 0.85 | USP10 (0.53) | USP10ALDH1A1MAPT | |
| SCHEMBL1924142 | 0.84 | TSPO (0.43) | USP10POLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064185-B1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INT (ES) | 2011-06-08 | — | — | EP | claimed |
| US-20100168099-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL, S.A. (ES) | 2010-07-01 | — | — | US | claimed |
| CN-101522630-A | 1H-quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | FERRER INT (ES) | 2009-09-02 | — | — | CN | claimed |
| EP-2064185-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | Ferrer Internacional, S.A. (ES) | 2009-06-03 | — | — | EP | claimed |
| WO-2008017710-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL S.A. (ES) | 2008-02-14 | — | — | WO | claimed |
| EP-1886996-A1 | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2008-02-13 | — | — | EP | claimed |
| EP-2064185-B1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INT (ES) | 2011-06-08 | — | — | EP | disclosed |
| US-20100168099-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL, S.A. (ES) | 2010-07-01 | — | — | US | disclosed |
| CN-101522630-A | 1H-quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | FERRER INT (ES) | 2009-09-02 | — | — | CN | disclosed |
| EP-2064185-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | Ferrer Internacional, S.A. (ES) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008017710-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL S.A. (ES) | 2008-02-14 | — | — | WO | disclosed |
| EP-1886996-A1 | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168099-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | GABRA1, GABRA4, GABRA2 | USP10 3340/4885PTGDR2 546/4885MCL1 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.